Lexeo Therapeutics (LXEO) News Today $5.12 +0.64 (+14.29%) Closing price 04:00 PM EasternExtended Trading$5.12 +0.00 (+0.10%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceMay 19 at 7:00 AM | globenewswire.comLXEO Share News TodayMay 16, 2026 | uk.investing.comLexeo Therapeutics (NASDAQ:LXEO) Rating Increased to Hold at Wall Street ZenMay 16, 2026 | americanbankingnews.comLexeo Therapeutics (NASDAQ:LXEO) Receives Buy Rating from Chardan CapitalMay 12, 2026 | americanbankingnews.comChardan Capital Reaffirms "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO)May 11, 2026 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Announces Earnings ResultsMay 11, 2026 | marketbeat.comLexeo Highlights Q1 Progress Advancing Cardiac Gene TherapiesMay 11, 2026 | tipranks.comLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational HighlightsMay 11, 2026 | globenewswire.comLexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by BrokeragesMay 2, 2026 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street ZenMay 2, 2026 | marketbeat.comLexeo Therapeutics Adds Genomic Medicine Leader to BoardApril 30, 2026 | tipranks.comLexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Should You Buy?April 29, 2026 | marketbeat.comLexeo Therapeutics to Present New Cardiac Gene Therapy Data at ASGCT Annual Meeting 2026April 27, 2026 | quiverquant.comQLexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingApril 27, 2026 | markets.businessinsider.comLexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingApril 27, 2026 | globenewswire.comLexeo Therapeutics (NASDAQ:LXEO) CEO Sells $312,950.00 in StockApril 8, 2026 | insidertrades.comWill Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely?April 1, 2026 | finance.yahoo.comLexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens FinancesMarch 30, 2026 | tipranks.comLexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsMarch 30, 2026 | globenewswire.comLexeo Therapeutics to Participate in the Leerink Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comLexeo Therapeutics (NASDAQ:LXEO) COO Jose Manuel Otero Sells 3,016 SharesFebruary 21, 2026 | insidertrades.comLexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptFebruary 13, 2026 | seekingalpha.comLexeo Therapeutics to Participate in Upcoming Investor Conferences in FebruaryFebruary 5, 2026 | globenewswire.comHC Wainwright says market remains unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 programFebruary 2, 2026 | msn.comLexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA TherapeuticsJanuary 27, 2026 | globenewswire.comLexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comLexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 14, 2026 | seekingalpha.comLexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy - SlideshowJanuary 12, 2026 | seekingalpha.comLexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy TranscriptJanuary 12, 2026 | seekingalpha.comLexeo Therapeutics stock falls after PKP2 gene therapy dataJanuary 12, 2026 | za.investing.comLexeo Therapeutics shares slide following PKP2 gene therapy updateJanuary 12, 2026 | msn.comLexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic CardiomyopathyJanuary 12, 2026 | quiverquant.comQLexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic CardiomyopathyJanuary 12, 2026 | globenewswire.comLexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene TherapyJanuary 9, 2026 | markets.businessinsider.comWall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy PipelineDecember 27, 2025 | insidermonkey.com13 Best Get Rich Fast Stocks to Buy Right NowDecember 26, 2025 | insidermonkey.comRaymond James sees an attractive setup in these 2 'strong buy' stocksDecember 25, 2025 | msn.comLexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceDecember 22, 2025 | globenewswire.comRaymond James initiates coverage of Lexeo Therapeutics (LXEO) with strong buy recommendationDecember 18, 2025 | msn.comLexeo Therapeutics initiated with a strong buy at Raymond JamesDecember 18, 2025 | msn.comChardan Capital maintains Lexeo Therapeutics (LXEO) buy recommendationDecember 12, 2025 | msn.comLexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy TranscriptDecember 9, 2025 | seekingalpha.comLexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) ForumDecember 4, 2025 | finance.yahoo.comLexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) ForumDecember 4, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of Lexeo Therapeutics (LXEO) with Overweight RecommendationNovember 21, 2025 | msn.comLexeo Therapeutics initiated with an Overweight at Cantor FitzgeraldNovember 20, 2025 | msn.comOptimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety ProfileNovember 17, 2025 | tipranks.comLexeo Therapeutics: Behind The ReboundNovember 6, 2025 | seekingalpha.comLexeo Therapeutics Reports Positive Interim Data for LX2006 and Progress Towards Pivotal Study Amid $154 Million FinancingNovember 5, 2025 | quiverquant.comQ Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXEO Media Mentions By Week LXEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼0.410.39▲Average Medical News Sentiment LXEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼33▲LXEO Articles Average Week Get the Latest News and Ratings for LXEO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Lexeo Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Mesoblast News Today Syndax Pharmaceuticals News Today Capricor Therapeutics News Today Rapport Therapeutics News Today Lakefront Biotherapeutics American Depositary Shares News Today Oculis News Today MBX Biosciences News Today ANI Pharmaceuticals News Today Harmony Biosciences News Today Palvella Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextJim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...Paradigm Press | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe $700 billion buy signal most investors are completely ignoringAmazon, Google, Meta, and Microsoft have committed $700 billion to AI infrastructure this year - more capital ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
